Trading Halt Update by DS Healthcare Group Inc.
POMPANO BEACH, FL / ACCESSWIRE / March 8, 2017 / DS Healthcare Group, Inc. (DSKX) ("DS Healthcare" or the "Company") announced today that the Company encountered certain unforeseen delays to resume trading on a new exchange.
We have engaged the services of a market maker that had filed a 15-c211 form on the Company's behalf. The form was filed with FINRA on January 31, 2017, and, according to the information available at that time, the re-listing process was expected to take approximately 2 to 3 weeks from the date of filing. The Company was further advised this week that the process is expected to take longer than the original 2-3 weeks. The Company continues to work through its market maker with FINRA and our securities will begin trading the moment FINRA provides clearance. Another announcement will follow shortly several days before trading will resume.
About DS Healthcare Group
DS Healthcare Group Inc. is a leader in the development of biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, and pharmacies. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan," or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.
Contact:
Investor Relations
DS Healthcare Group
(888) 404-7770 ext. 3
Investors@DSHealthgroup.com
SOURCE: DS Healthcare Group
